Michele M Merten1, M Regina Castro1, Jun Zhang2, Jolanta Durski3, Mabel Ryder1,4. 1. 1 Division of Endocrinology, Mayo Clinic , Rochester, Minnesota. 2. 2 Division of Laboratory Medicine/Pathology, Mayo Clinic , Rochester, Minnesota. 3. 3 Department of Radiology, Mayo Clinic , Rochester, Minnesota. 4. 4 Division of Medical Oncology, Mayo Clinic , Rochester, Minnesota.
Abstract
BACKGROUND: Cytologically defined indeterminate thyroid nodules are a diagnostic challenge. Surgical lobectomy remains the gold standard for definitive diagnosis. However, 70-85% of nodules are ultimately benign. The primary objective of this study was to evaluate the negative predictive value (NPV) of F18-fluorodeoxyglucose (FDG) positron emission computed tomography (PET/CT) in excluding cancer among cytologically indeterminate thyroid nodules within the authors' institution using surgical pathology as the gold-standard reference. In addition, a systematic review was performed of published prospective studies on the NPV of PET/CT in evaluating indeterminate thyroid nodules. METHODS: A retrospective review was performed of all patients aged ≥18 years seen at the Mayo Clinic between January 1, 2000, and December 31, 2014, with cytologically defined indeterminate thyroid nodules (suspicious for Hürthle cell neoplasm or follicular neoplasm; N = 858), who had a PET/CT within one year of fine-needle aspiration (n = 80) and underwent definitive diagnostic lobectomy (n = 51). Nodules were considered PET negative if they had a standardized uptake value (SUV) <5. Additionally, a systematic review was performed of published prospective studies on the NPV of PET/CT across multiple sites. RESULTS: Fifty-one patients met the eligibility criteria. The retrospective review combined with a systematic review of eight prospective studies suggests that indeterminate nodules with a negative PET (SUV <5) have a low risk of malignancy (NPV 94%). The cancer prevalence in the institution is 14% and 27% in the combined prospective studies. CONCLUSIONS: PET/CT represents a preoperative, non-invasive tool that when combined with sonographic features can identify indeterminate nodules at low risk for malignancy.
BACKGROUND: Cytologically defined indeterminate thyroid nodules are a diagnostic challenge. Surgical lobectomy remains the gold standard for definitive diagnosis. However, 70-85% of nodules are ultimately benign. The primary objective of this study was to evaluate the negative predictive value (NPV) of F18-fluorodeoxyglucose (FDG) positron emission computed tomography (PET/CT) in excluding cancer among cytologically indeterminate thyroid nodules within the authors' institution using surgical pathology as the gold-standard reference. In addition, a systematic review was performed of published prospective studies on the NPV of PET/CT in evaluating indeterminate thyroid nodules. METHODS: A retrospective review was performed of all patients aged ≥18 years seen at the Mayo Clinic between January 1, 2000, and December 31, 2014, with cytologically defined indeterminate thyroid nodules (suspicious for Hürthle cell neoplasm or follicular neoplasm; N = 858), who had a PET/CT within one year of fine-needle aspiration (n = 80) and underwent definitive diagnostic lobectomy (n = 51). Nodules were considered PET negative if they had a standardized uptake value (SUV) <5. Additionally, a systematic review was performed of published prospective studies on the NPV of PET/CT across multiple sites. RESULTS: Fifty-one patients met the eligibility criteria. The retrospective review combined with a systematic review of eight prospective studies suggests that indeterminate nodules with a negative PET (SUV <5) have a low risk of malignancy (NPV 94%). The cancer prevalence in the institution is 14% and 27% in the combined prospective studies. CONCLUSIONS: PET/CT represents a preoperative, non-invasive tool that when combined with sonographic features can identify indeterminate nodules at low risk for malignancy.
Authors: Luca Giovanella; Anca M Avram; Ioannis Iakovou; Jennifer Kwak; Susan A Lawson; Elizabeth Lulaj; Markus Luster; Arnoldo Piccardo; Matthias Schmidt; Mark Tulchinsky; Frederick A Verburg; Ely Wolin Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-07 Impact factor: 9.236
Authors: Mayumi Endo; Jennifer A Sipos; Matthew D Ringel; Kyle Porter; Haikady N Nagaraja; John E Phay; Lawrence A Shirley; Clarine Long; Chadwick L Wright; Katie Roll; Fadi A Nabhan Journal: Cancer Med Date: 2021-01-15 Impact factor: 4.452
Authors: Elizabeth J de Koster; Wyanne A Noortman; Jacob M Mostert; Jan Booij; Catherine B Brouwer; Bart de Keizer; John M H de Klerk; Wim J G Oyen; Floris H P van Velden; Lioe-Fee de Geus-Oei; Dennis Vriens Journal: Eur J Nucl Med Mol Imaging Date: 2022-02-09 Impact factor: 10.057
Authors: Elizabeth J de Koster; Lioe-Fee de Geus-Oei; Adrienne H Brouwers; Eveline W C M van Dam; Lioe-Ting Dijkhorst-Oei; Adriana C H van Engen-van Grunsven; Wilbert B van den Hout; Tamira K Klooker; Romana T Netea-Maier; Marieke Snel; Wim J G Oyen; Dennis Vriens Journal: Eur J Nucl Med Mol Imaging Date: 2022-01-04 Impact factor: 10.057